Navigation Links
Monogram and Dana-Farber Cancer Institute Initiate Evaluation of HERmark(TM) Breast Cancer Assay in Metastatic Breast Cancer
Date:9/23/2008

ents a novel approach to the study of HER2- positive breast cancer by virtue of its ability to make accurate measurements of HER2 and its homodimer in actual breast tumors," said Ian Krop, M.D., Ph.D., Assistant Professor of Medicine, Division of Medical Oncology at the Dana Farber Cancer Institute and principal investigator of the study. "We look forward to working with Monogram on this study to try to develop a better understanding of the biology of HER2 positive breast cancer and the biomarkers that influence its clinical outcome."

About HERmark

HERmark is a proprietary diagnostic that accurately quantifies HER2 total protein levels and HER2 homodimerization in patients with breast cancer. HERmark is a CLIA-validated assay that is performed exclusively in Monogram's CAP-certified clinical reference laboratory in South San Francisco. Robust, accurate, sensitive and reproducible measurements of HER2 status are reported to physicians with a turnaround time of 7 days.

With the accurate measurements provided by HERmark, it is expected that as many as 15-20% of patients determined by conventional technologies to be HER2- negative would be reclassified by HERmark.

About Monogram

Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved anti-viral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at http://www.monogrambio.com.

About Dana-Farber Cancer Institute

Dana-Farber Cancer Institute is a p
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
2. Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors
3. Monogram Biosciences Announces Second Quarter 2008 Financial Results Conference Call
4. Monogram Biosciences to Present at the Collins Stewart Fourth Annual Growth Conference
5. Sensitivity Enhancements to Monograms Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
6. Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting
7. Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting
8. Monogram Biosciences Announces First Quarter 2008 Financial Results Conference Call
9. Monogram Biosciences to Present at the JMP Securities Seventh Annual Research Conference
10. Raven biotechnologies Announces Collaboration With Monogram Biosciences to Advance Diagnostic Cancer Technologies
11. Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Aug. 3, 2015  MiMedx Group, Inc. (NASDAQ: ... amniotic tissue and patent-protected processes to develop and market ... Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of ... 35 th Annual Canaccord|Genuity Growth Conference in ... Chairman and CEO, William C. Taylor , President ...
(Date:8/3/2015)... Aug. 3, 2015  Aethlon Medical, Inc. (Nasdaq: AEMD ... treat life-threatening diseases, today announced that it will host ... webcast on Thursday, August 13, 2015 at 4:30 p.m. ... follow the release of fiscal 2016 first quarter results.  ... approximately two hours after the call at the Investor ...
(Date:8/3/2015)... Aug. 3, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: ... on the development of autologous cell therapies, announced today that ... the InvestMNT conference held in Minneapolis, Minnesota ... time. Hall,s presentation will highlight RepliCel,s 18-month milestones including CE ... Europe , clinical data from both RCT-01 (tendon) ...
(Date:7/31/2015)... , July 31, 2015 China Cord ... China,s leading provider of cord blood ... cell storage services, today announced that the Company has ... U.S. Securities and Exchange Commission. The filed Form 20-F ... March 31, 2015. The Form 20-F can be accessed ...
Breaking Biology Technology:MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2RepliCel Presenting at InvestMNT Investor Conference in Minneapolis 2China Cord Blood Corporation Files Its Annual Report on Form 20-F 2
... ... ... Xybion Corporation announced today that it has completed the acquisition of substantially all of ... The terms of the transactions were not disclosed., , ,Stelex and Vital-Path, based in Bensalem, ...
... CHENGDU, China , May 12 /PRNewswire-Asia-FirstCall/ -- Tianyin,Pharmaceutical ... in the modernized traditional Chinese medicine ("TCM") and branded,generics today announced ... , , Third quarter fiscal year 2010 ending ... revenue increased 60% year over year to $15.9 million, net, ...
... This release is available in French . Physicists ... energy involved in adding electrons to semi-conductor nanocrystals, also known ... and other areas of science. Dr. Peter Grtter, McGill,s Associate ... that his research team has developed a cantilever force sensor ...
Cached Biology Technology:Xybion Completes Acquisition of Stelex and Vital-Path, Leaders in Business Process Software and Consulting Services for Regulated Industries, from GE Healthcare 2Xybion Completes Acquisition of Stelex and Vital-Path, Leaders in Business Process Software and Consulting Services for Regulated Industries, from GE Healthcare 3Tianyin Reports Record Third Quarter 2010 Financial Results 2Tianyin Reports Record Third Quarter 2010 Financial Results 3Tianyin Reports Record Third Quarter 2010 Financial Results 4Tianyin Reports Record Third Quarter 2010 Financial Results 5Tianyin Reports Record Third Quarter 2010 Financial Results 6Tianyin Reports Record Third Quarter 2010 Financial Results 7Tianyin Reports Record Third Quarter 2010 Financial Results 8Tianyin Reports Record Third Quarter 2010 Financial Results 9Tianyin Reports Record Third Quarter 2010 Financial Results 10Tianyin Reports Record Third Quarter 2010 Financial Results 11Tianyin Reports Record Third Quarter 2010 Financial Results 12Tianyin Reports Record Third Quarter 2010 Financial Results 13Quantum move toward next generation computing 2
(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... wallet, announces that it has filed provisional patent ... Method. This invention highlights next ... authorizes an account, but also the user using ...
(Date:7/20/2015)... July 20, 2015  Acuity Market Intelligence,s latest ... Convergence of Commerce and Privacy" forecasts that between ... apps will be downloaded to smart mobile devices ... biometrics market is projected to generate more than ... the seven-year forecast period.    "Biometrics ...
(Date:7/13/2015)... , Jul. 13, 2015 NXT-ID, Inc. ... a biometric authentication company focused on the growing ... filed provisional patent 62/188684 for BEHAVIORAL-DIRECTED ... another new convenient and secure method to make ... innovative payment methods, introduced with its groundbreaking voice-direct ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
... a species of alfalfa from Siberia, to the United States. His ... But what also happened during this time in the late ... of the matter is creating a current revival in both interest ... And several researchers members of the American Society of Agronomy (ASA) ...
... 31st, 2012.- Madrid will become international destination for ... Innovation Conference 2012, focused on building high performance ... This new organization has been created by the ... Government of the Comunidad de Madrid, through the ...
... CRUZ, CA--Researchers at the University of California, Santa Cruz, ... from wounds and skin infections, using light to trigger ... developed a photoactive compound that releases nitric oxide when ... biocompatible material that could be applied as a sprayable ...
Cached Biology News:Time is ticking for some crop's wild relatives 2MADRID-MIT M+Vision Consortium hosts Biomedical Innovation Conference 2012 2Light-induced delivery of nitric oxide eradicates drug-resistant bacteria 2Light-induced delivery of nitric oxide eradicates drug-resistant bacteria 3
Liquid. PBS containing 10 mM NaN 3 . AVOID FREEZE/THAW CYCLES. Recognizes α1, 2, 3, 5, 6 and 7 subunits of 20S proteasome. ...
AVOID FREEZE/THAW CYCLES. Recognizes the UCP-2 protein....
Mouse monoclonal antibody to Lats2....
Rabbit Anti-Human Janus Kinase 2 (JAK2 Polyclonal Antibody Family: Protein Kinase Sub-Family: TYK2/JAK Applications: ELISA, Western Blot...
Biology Products: